Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
SUMITOMO DAINIPPON PHARMA CO., LTD. et al v. MSN LABORATORIES PRIVATE LTD. et al
Case Number:
2:17-cv-01010
Court:
Nature of Suit:
Judge:
Firms
Sectors & Industries:
-
July 05, 2018
MSN, Sandoz Settle Sunovion's IP Suit Over Latuda Generics
A New Jersey federal judge Thursday dismissed Sunovion Pharmaceuticals Inc.'s patent infringement suit against MSN Laboratories and Sandoz Inc. over its bipolar medication Latuda after the parties reached a deal and MSN agreed to delay its generic version of the drug until Sunovion's patent expires.
-
February 15, 2017
Sunovion Gets 2 Latuda Generics Blocked, Sues Over A 3rd
A New Jersey federal judge on Tuesday blocked Emcure Pharmaceuticals Ltd. and Teva Pharmaceutical Industries Ltd. from moving forward with generic versions of Sunovion Pharmaceuticals Inc.'s bipolar disorder medication Latuda, and that same day, Sunovion filed another infringement suit against MSN Laboratories and Sandoz Inc. over the drug.